Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844959 | 0.76 | CYP2A6 (0.44) | CYP1A2CYP2A6TRPV1MAPTL3MBTL1 | |
| SCHEMBL1026222 | 0.73 | MAP4K1 (0.43) | CYP1A2CYP2A6TRPV1MAPTL3MBTL1 | |
| SCHEMBL13520217 | 0.69 | CYP1A2 (0.53) | CYP1A2CYP2A6MAPTL3MBTL1 | |
| SCHEMBL1026820 | 0.68 | CYP1A2 (0.36) | CYP1A2CYP2A6TRPV1 | |
| SCHEMBL1029267 | 0.68 | DCTPP1 (0.38) | CYP1A2CYP2A6MAPT | |
| SCHEMBL17532785 | 0.66 | CYP1A2 (0.54) | CYP1A2CYP2A6TRPV1MAPT | |
| SCHEMBL14341058 | 0.64 | CYP2A6 (0.61) | CYP1A2CYP2A6MAPTL3MBTL1 | |
| SCHEMBL17532745 | 0.64 | CCR1 (0.54) | CYP1A2CYP2A6MAPT | |
| SCHEMBL14970137 | 0.64 | CYP1A2 (0.41) | CYP1A2CYP2A6MAPTL3MBTL1 | |
| SCHEMBL1028986 | 0.63 | KDM4E (0.43) | TRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | CYP1A2 80/4885CYP2A6 257/4885TRPV1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.